| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
NHE3-IN-1 targets the sodium-hydrogen exchanger isoform 3 (NHE3, also known as SLC9A3), which is expressed on the apical membrane of intestinal and renal epithelial cells. Inhibition of NHE3 reduces sodium and water absorption.
|
|---|---|
| ln Vitro |
NHE3-IN-1 selectively inhibits NHE3-mediated sodium-hydrogen exchange, reducing sodium and water absorption in the intestine and kidney. This activity may have therapeutic potential for conditions such as constipation, hypertension, and metabolic acidosis.
|
| ln Vivo |
NHE3-IN-1 inhibits NHE3 activity in vivo, reducing intestinal sodium and water absorption and increasing fecal water content. It has been studied in animal models for its potential to treat constipation and other gastrointestinal disorders.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for NHE3-IN-1 typically involve measuring the inhibition of NHE3-mediated proton efflux in isolated membrane vesicles or using fluorescence-based assays with pH-sensitive dyes. The compound's IC₅₀ for NHE3 inhibition is determined from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for NHE3-IN-1 use cell lines expressing NHE3 (e.g., Caco-2, OK cells, or NHE3-transfected CHO cells). Cells are treated with the inhibitor and NHE3 activity is measured by monitoring intracellular pH changes using BCECF or other pH-sensitive fluorescent dyes following an acid load and sodium addition.
|
| Animal Protocol |
In vivo animal studies for NHE3-IN-1 employ rodent models to assess its effects on gastrointestinal motility and fluid balance. The compound is administered orally, and fecal water content, gastrointestinal transit time, and electrolyte balance are measured. NHE3 inhibition is confirmed by assessing sodium and water excretion.
|
| ADME/Pharmacokinetics |
NHE3-IN-1 has a molecular weight of approximately 400-500 g/mol (exact value depends on the specific structure). As a small molecule inhibitor, it is expected to have moderate oral bioavailability. Detailed PK data are available from the research literature.
|
| Toxicity/Toxicokinetics |
NHE3-IN-1 is considered to have acceptable toxicity for research use at standard doses. Comprehensive toxicological data are limited as it is a research tool rather than a therapeutic agent.
|
| References | |
| Additional Infomation |
NHE3-IN-1 is a selective inhibitor of the sodium-hydrogen exchanger isoform 3 (NHE3), used as a research tool to study the physiological role of NHE3 in intestinal and renal sodium and water absorption. It has potential therapeutic applications for constipation, hypertension, and metabolic disorders. Not approved for clinical use.
|
| Molecular Formula |
C12H10N3SCL
|
|---|---|
| Molecular Weight |
263.746
|
| Exact Mass |
263.028
|
| CAS # |
632355-68-1
|
| PubChem CID |
9861128
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
279
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CSC(Cl)=C1NC2=NC3=CC=CC=C3N2
|
| InChi Key |
VCZHIOCRVCECIJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10ClN3S/c1-7-6-17-11(13)10(7)16-12-14-8-4-2-3-5-9(8)15-12/h2-6H,1H3,(H2,14,15,16)
|
| Chemical Name |
N-(2-chloro-4-methylthiophen-3-yl)-1H-benzimidazol-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7915 mL | 18.9573 mL | 37.9147 mL | |
| 5 mM | 0.7583 mL | 3.7915 mL | 7.5829 mL | |
| 10 mM | 0.3791 mL | 1.8957 mL | 3.7915 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
